Occam Places CEO for UK-Based Laverock Therapeutics
In November 2026, Occam Global placed Parker Moss as CEO of Laverock Therapeutics, a London-based CAR-T oncology biotech. Parker also joins Laverock’s Board of Directors.
Parker brings a career spanning cancer genomics, AI-driven drug discovery, RNA medicines, and RNA manufacturing. Most recently, he served as Program Director of Wellcome Leap’s RNA Readiness + Response Global (R3G) program, where he led a $150 million investment in RNA design and manufacturing technology. Before that, he was EVP of Corporate Development at Exscientia, where he led the company through its acquisition by Recursion. Earlier, he was CCO at Genomics England, where he led its cancer program, and CBO at Owkin.
Parker holds a degree in Physics and Philosophy from Durham University.

View recent Placements



.jpg)
DISCOVER OCCAM GLOBAL
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies.
Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.